DNA methylation cancer biomarkers: translation to the clinic
Carcinogenesis is accompanied by widespread DNA methylation changes within the cell.
These changes are characterized by a globally hypomethylated genome with focal …
These changes are characterized by a globally hypomethylated genome with focal …
Human papillomavirus vaccines: an updated review
L Cheng, Y Wang, J Du - Vaccines, 2020 - mdpi.com
Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past
decade, have shown promising results in decreasing HPV infection and related diseases …
decade, have shown promising results in decreasing HPV infection and related diseases …
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen… - … England Journal of …, 2015 - Mass Medical Soc
Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
C Simoens, PPL Martin‐Hirsch - Cochrane database of …, 2018 - cochranelibrary.com
Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …
causally linked with the development of cervical precancer and cancer. HPV types 16 and …
Global burden of human papillomavirus and related diseases
D Forman, C de Martel, CJ Lacey, I Soerjomataram… - Vaccine, 2012 - Elsevier
The worldwide prevalence of infection with human papillomavirus (HPV) in women without
cervical abnormalities is 11–12% with higher rates in sub-Saharan Africa (24%), Eastern …
cervical abnormalities is 11–12% with higher rates in sub-Saharan Africa (24%), Eastern …
Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)–associated cancers and HPV …
Abstract Background The American Cancer Society (ACS), the Centers for Disease Control
and Prevention (CDC), the National Cancer Institute (NCI), and the North American …
and Prevention (CDC), the National Cancer Institute (NCI), and the North American …
Prevalence of HPV after introduction of the vaccination program in the United States
LE Markowitz, G Liu, S Hariri, M Steinau, EF Dunne… - …, 2016 - publications.aap.org
BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been
recommended for females aged 11 to 12 years and through 26 years if not previously …
recommended for females aged 11 to 12 years and through 26 years if not previously …
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition …
LE Markowitz, S Hariri, C Lin, EF Dunne… - The Journal of …, 2013 - academic.oup.com
Background. Human papillomavirus (HPV) vaccination was introduced into the routine
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
SN Tabrizi, JML Brotherton, JM Kaldor… - The Lancet infectious …, 2014 - thelancet.com
Background After the introduction of a quadrivalent human papillomavirus (HPV) vaccination
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …